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CD95L as a key regulator for the PD-associated altera-
tion of circulating monocytes. Pharmacological neutrali-
zation of CD95L reverses the dysregulation of monocytic 
subpopulations in favor of non-classical monocytes. Our 
results suggest that PD monocytes are in an inflammatory 
predisposition responding with hyperactivation to a “sec-
ond hit”. These results provide the first direct evidence that 
circulating human peripheral blood monocytes are altered 
in terms of their function and composition in PD patients. 
This study provides insights into monocyte biology in PD 
and establishes a basis for future studies on peripheral 
inflammation.
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Introduction
Parkinson’s disease (PD) is a chronic progressive neuro-
degenerative disease characterized by a progressive loss 
of neurons in the substantia nigra and other brain regions. 
However, the underlying pathomechanisms leading to neu-
ronal death are currently unknown. While several mecha-
nisms (e.g., protein aggregation, mitochondrial dysfunction 
and others) have been discussed as potential pathophysi-
ological pathways, emerging evidence indicates that the 
immune system also plays a critical role in the pathogen-
esis of PD. For example, CNS neuroinflammation is rec-
ognized as a hallmark in PD [3] and genome-wide associa-
tion studies have linked polymorphisms in immune genes 
as risk factors for PD [42]. In contrast to the wealth of 
studies on neuroinflammatory processes in the CNS of PD 
patients (see review [17]), the particular state of the periph-
eral innate immune system during PD is not understood. 
Abstract Despite extensive effort on studying inflam-
matory processes in the CNS of Parkinson’s disease (PD) 
patients, implications of peripheral monocytes are still 
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hensive picture of circulating myeloid cells in PD patients. 
We applied a human primary monocyte culture system and 
flow cytometry-based techniques to determine the state of 
monocytes from PD patients during disease. We found that 
the classical monocytes are enriched in the blood of PD 
patients along with an increase in the monocyte-recruiting 
chemoattractant protein CCL2. Moreover, we found that 
monocytes from PD patients display a pathological hyper-
activity in response to LPS stimulation that correlates with 
disease severity. Inflammatory pre-conditioning was also 
reflected on the transcriptome in PD monocytes using next-
generation sequencing. Further, we identified the CD95/
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To date, some studies have shown elevated levels of serum 
cytokines (IL-2, IL-4, IL-6, IL-10, TNFα) in PD patients 
[11, 35, 40] as first general evidence of immune dysregu-
lation. Specifically, peripheral blood mononuclear cells 
(PBMCs) are suspected to contribute to peripheral cytokine 
elevation but conclusive evidence in humans is largely 
missing. In an animal model for PD [18] and other neurode-
generative diseases [2, 9, 38], invasion of peripheral mono-
cytes into the CNS has been demonstrated. Butovsky et 
al. [10] have clearly shown that monocytes which migrate 
into the mouse CNS are a distinct functional entity with 
different functional properties than CNS-resident micro-
glia. Peripherally activated monocytes could thus have a 
tremendous impact on CNS inflammation but the existence 
and mode of peripheral innate inflammation in PD patients 
remain unclear to date.
In mice, two subsets of circulating monocytes based 
on their differential expression of CCR2 and CX3CR1 
can be distinguished. The so-called “inflammatory mono-
cytes” (Ly6ChiCCR2-highCx3CR1low) with a pronounced 
pro-inflammatory cytokine profile are highly mobile and 
rapidly recruited to inflamed tissue. They can be differ-
entiated from “resident” monocytes (Ly6CloCCR2lowCX-
3CR1high) that are important for regeneration and patrol 
along blood vessels [4, 24, 36]. Interestingly, recruitment 
of Ly6Chi monocytes into the inflamed CNS has previously 
been reported in mouse models [10, 32]. In humans, equiv-
alent subsets of monocytes can be distinguished based on 
the expression of CD14 and CD16. In detail, Ly6Chi and 
LyC6lo correspond to CD14+CD16− and CD14+CD16+ 
and are known as “classical” and “non-classical” mono-
cytes, respectively [13].
Little is known about how different monocyte sub-
populations are balanced in humans. The FAS/FAS ligand 
(FASLG) system can contribute to inflammatory reactions 
by mediating the release of cytokines from myeloid cells 
[34] and triggering the recruitment of peripheral mono-
cytes and macrophages to the site of inflammation [5, 12]. 
Upregulation of FASLG expression in peripheral blood 
myeloid cells in rodents and in humans was found to be 
required for the recruitment of peripheral myeloid cells to 
the injured tissue. FASLG contributes to neuronal cell loss 
by regulating the differentiation and function of peripheral 
myeloid cells, rather than via direct FAS-induced apop-
tosis in FAS-bearing neural cells [31]. Even though there 
have been studies on the FAS/FASLG system in the con-
text of apoptosis and PD in animal models [20, 28, 30], 
its involvement in inflammation and dysregulation in PD 
patients is still elusive. Specifically, the effect of FASLG on 
myeloid cells in the periphery and its potential role in the 
regulation of different monocyte subpopulations in humans 
have not yet been investigated.
Therefore, the aim of this study was a comprehensive 
characterization of circulating myeloid cells of PD patients 
and to understand their particular state during PD. Using a 
primary model for human monocytes, we examined the cor-
relation between human monocyte functionality and clini-
cal features of PD. We applied next-generation sequencing 
to explore the transcriptome of PD monocytes compared 
to age-matched healthy controls. We further studied the 
involvement of the FAS/FASLG system in monocyte regu-
lation in PD and assessed its therapeutic consequences on 
monocyte function.
Materials and methods
All chemicals used were purchased from Sigma Aldrich 
(Munich, Germany) unless stated otherwise.
Ethical approval and study cohort
All human experiments were performed in accordance 
with the declaration of Helsinki and approved by the Ethics 
Committee of Ulm University. All study participants gave 
informed written consent to participate in the study.
PD patients as well as healthy controls were recruited 
at the University and rehab hospital Ulm (RKU). Healthy 
controls were chosen to match the patient cohort’s char-
acteristics. A detailed description of the patient cohort 
for each experiment can be found as Supplementary 
Tables 1–5. In general, PD patients with confounding 
factors affecting the immune system were excluded for 
all experiments. PD patients with other co-morbidities 
like hypertension or depression were included in the 
study (see Supplementary Tables 1–5). All PD patients 
included in the study were diagnosed using the UK PD 
Society Brain Bank clinical diagnostic criteria at the 
RKU which is a specialized center for PD. Using a stand-
ard procedure peripheral venous blood in non-fasting 
state was collected with a Monovette™ blood drawing 
system (Sarstedt, Germany) and processed within 3 h 
post-collection. For isolation of peripheral blood leu-
kocytes, EDTA was used as anticoagulant. Li-Heparin 
monovettes (Sarstedt, Germany) were used for the collec-
tion of whole blood for flow cytometry. For determina-
tion of peripheral blood levels of cytokines, serum col-
lection tubes (Sarstedt, Germany) were used. Patients 
and healthy controls were age and sex matched. For age 
matching, both groups were designed to have no signifi-
cant difference in age when comparing average, median 
and range. For sex matching, differences between inves-
tigated groups were no more than 10 % in advantage of 
either gender.
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Staging of PD progression with Hoehn & Yahr staging 
system
To assess the progression of PD in patients, the modified 
Hoehn & Yahr staging system was used [29]. A score of 0 
indicates no detectable signs of disease and was assigned to 
all healthy controls. Disease progression is broken down to 
seven stages (including 1.5 and 2.5 in the modified version 
of the system) ranging from mild unilateral involvement 
(1.0) to confinement to wheelchair or bed (5.0).
Isolation of peripheral blood mononuclear cells 
and purification of peripheral blood monocytes
Peripheral blood mononuclear cells were isolated from 
venous whole blood by density centrifugation on Histo-
paque® density gradient. After two subsequent washes to 
get rid of contaminating platelets, cells were labeled with 
magnetic beads coupled to monoclonal antibodies against 
CD14 (Miltenyi Biotec, Germany) and CD14-positive cells 
separated in a column placed in a strong magnetic field 
(Miltenyi Biotec, Germany). Subsequently, the column was 
removed from the magnetic field and the retracted cells 
eluted with MACS™ buffer (Miltenyi Biotec, Germany). 
For untouched monocytes isolation, non-monocytes were 
labeled with biotin-conjugated antibodies against CD3, 
CD7, CD16, CD19, CD56, CD123 and Glycophorin A, 
and Anti-Biotin MicroBeads (Miltenyi Biotec, Germany). 
The flow-through fraction represents the unlabeled mono-
cytes. Cells were then centrifuged at 300 g for 10 min at 
RT and resuspended in cell culture medium (RPMI 1640, 
10 % FCS (PAA, Austria), 1 % penicillin/streptomycin 
(PAA, Austria) or RLT-lysis buffer (Qiagen, The Nether-
lands) for further applications. The purity of the isolated 
cell population was controlled by flow cytometry analysis 
and immunocytochemistry.
Monocyte culture and stimulation
To functionally characterize monocyte activation, mono-
cytes were plated on uncoated culture plates (24-well, BD 
Biosciences, USA) at a density of 106 cells/ml (5.105 cells 
per 24-well). Monocytes were allowed to rest for 24 h prior 
to the LPS stimulation (1 ng/ml, [15]) to eradicate the influ-
ence of mechanical/chemical/temperature stress during the 
isolation procedure on experimental results. Monocytes 
were cultured in sterile RPMI 1640 medium supplemented 
with 10 % v/v fetal calf serum (FCS, PAA, Austria) and 
1 % v/v penicillin–streptomycin (P/S; 1,000 U/ml, PAA, 
Austria). Sterile culture medium was used as a negative 
control for monocyte stimulation. LPS stimulation was per-
formed in duplicates. After 24 h stimulation, the superna-
tant was collected and the cells were lysed with extraction 
lysis buffer (1 M NaCl, 0.6 % w/v sodium deoxycholate, 
0.6 % v/v Igepal, 5 % v/v 1 M Tris pH 8.0, protease inhibi-
tor cocktail (Roche, Switzerland)).
Cytokine quantification in cell culture supernatants
Cytokine levels in culture supernatants were quantified 
by ELISA (IL-6, IL-10, CCL2, IFNγ, IL-1β; all antibody 
pairs obtained from BioLegend, USA) or with an electro-
chemiluminescence immunoassay (TNFα, IFN-8; Mes-
oScale Discovery, USA). Each standard and sample were 
measured by means of two replicates, average value calcu-
lated and blank absorption of matrix subtracted. A thresh-
old of 0.2 coefficient of variance (CV) was set as a limit 
to consider a value significant. Absorption values of known 
standards were plotted against concentrations and the 
resulting sigmoidal curve fitted using non-weighted five-
parameter logistics with ReaderFit™ (Hitachi Solutions, 
Japan). Cytokine release was normalized to cell number by 
quantification of protein concentration in cell lysate, meas-
ured by BCA assay (Thermo Scientific, USA) according to 
the supplier’s instructions.
FACS
Four milliliters of anticoagulated whole blood (Sarstedt, 
Germany) was collected in Li-Heparin monovettes from 
healthy volunteers and PD patients after informed consent. 
Osmotic lysis of red blood cells was performed with a red 
blood cell lysis buffer (RBC-LB: 50 mM NH4Cl, 70 mM 
NaHCO3, 0.1 % EDTA, dH2O). After lysis and washing 
with FACS buffer [PBS (Life Technologies) + 10 % FCS 
(PAA, Austria)], cells were resuspended in RPMI + 10 % 
FCS + 2 % P/S and treated 24 h or 48 h at 37 °C with vehi-
cle control (PBS) or APG101 (250 µg/ml). After incuba-
tion cells were resuspended, washed with FACS buffer and 
stained with anti-human antibodies specific for anti-HLA-
DR (1:200; Biolegend, USA, L243, Pe-Cy7), anti-CD14 
(1:200; BD, USA; M5E2, PerCP-Cy5.5), anti-CD16 (1:10; 
BD, 3G8, PE), anti-CD2 (1:20; eBioscience, USA RPA-
2.10, FITC), anti-CD335 (1:100; AbDSerotec, UK; 9E2, 
FITC), anti-CD15 (1:13; Miltenyi Biotec, VIMC6, FITC) 
and anti-CD19 (1:100; eBioscience, USA; HIB19, FITC) 
for 25 min at 4 °C in the dark. After washing, the stained 
cells were fixed 20 min in 2 % PFA, filtered (70 μm) and 
analyzed by flow cytometry (LSRII, BD) using appropri-
ate color compensation to correct for spectral overlap and 
autofluorescence. Therefore, following isotype controls 
were used at the same concentration as the primary antibod-
ies: mouse IgG2a, κ (Biolegend, USA MOPC-173, PE-Cy7), 
mouse IgG1, κ (eBioscience, USA, P3.6.2.8.1, FITC), 
mouse IgG2a, κ (BD, USA; G155-178, PerCP-Cy5.5), 
mouse IgG1, κ (BD, MOPC-21, PE). Monocytes are among 
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HLA-DR+ cells that do not express B-cell (CD19−), 
T-cell (CD2−), NK-cell (CD335−), or granulocyte makers 
(CD15−). Within this gate, CD14+ CD16− and CD14+ 
CD16+  monocytes, CD14− CD16+ monocytes and 
CD14− CD16− DCs can be separated. To exclude cell dou-
blets, cells were gated using area vs. width signal intensity. 
Data are presented as mean ± SEM from four independent 
experiments.
Next-generation sequencing and expression analysis
For whole-transcriptome analysis of expression, mono-
cytes were isolated from the peripheral blood of healthy 
controls and PD patients as described above and lysed 
with RLT buffer (Qiagen, The Netherlands). After isolation 
of total RNA (miRNeasy Mini Kit, Qiagen, The Nether-
lands), 200 ng total RNA was used for the generation of 
mRNA-focused libraries (TruSeq RNA Sample Prepara-
tion Kit v2, Set B, Illumina, USA). Clusters were gener-
ated with cBot (Illumina, USA) with the TruSeq SR Cluster 
Kit v3-cBot-HS (Illumina, USA). Samples were sequenced 
on a HiSeq 2000 sequencing system (Illumina, USA) 
with TruSeq SBS Kit HS-v3 (50 cycles). 52 bases were 
sequenced with single read and 2.0–2.5 × 107 reads per 
sample, 7 bases IndexRead.
For the unsupervised hierarchical clustering of subjects 
based on gene expression, genes with average expression 
among all samples <5 FPKM were excluded. Cosine cor-
relation and complete linkage were used for clustering 
with Genesis [39]. Heatmaps and cluster diagrams were 
generated with Genesis. For pathway analysis, genes were 
filtered by expression level (≥5 in at least one of the two 
groups to be compared), log ratio (log2 ≥ 1 or ≤−1) 
and significance of the difference (q value, significance 
corrected for multiple testing by Benjamini Hochberg, 
q ≤ 0.05) between the compared groups. Canonical path-
ways and upstream regulators were predicted by an Ingenu-
ity pathway analysis (Qiagen, The Netherlands); involved 
molecular functions and biological processes were identi-
fied with Genomatix genome analyser pathway system 
(Genomatix Software GmbH, Germany). For the identi-
fication of genes which are consistently expressed within 
the two groups to compare, we filtered out all genes whose 
expression pattern was determined by less than 25 % of the 
expression values. For heatmap generation, z scores were 
built for each value.
RT-qPCR
Total RNA was extracted using RNeasy Mini Kit (Qiagen, 
USA) in accordance with the manufacturer’s instructions. 
RNA concentration and quality were controlled using Nan-
oDrop (ThermoScientific, Waltham, MA, USA) and 1 µg 
of total RNA was used to synthesize cDNA using Iscript 
reverse transcriptase (Bio-Rad Laboratories) containing 
oligo-dT primers and random primers. cDNA was then 
diluted ten times and PCR analysis was performed on a 
Bio-Rad iCycler System using iQSYBR Green Supermix. A 
specific standard curve was performed in parallel for each 
gene to assess the specificity of the products, for quantifica-
tion of the respective transcripts in duplicate. PCR condi-
tions were 3 min at 95 °C, followed by 40 cycles of 30 s at 
94 °C and 10 s at 60 °C (for FASLG, 50 cycles of 20 s). The 
relative levels of each gene of interest were normalized to 
TBP, GAPDH (Fig. 5) and B2M (Fig. 2). Primers for FAS, 
FASLG and GAPDH were obtained from Qiagen. A list of 
all other primers used is provided in Supplementary Table 8.
Phagocytosis assay
Phagocytosis assay was performed as per supplier’s instruc-
tions with pHrodo™ Green Zymosan A BioParticles® (Life 
Technologies, Carlsbad, USA) conjugate for phagocytosis. 
In brief, monocytes were plated on a 96-well tissue culture 
plate and incubated in RPMI1640 10 % FCS 1 %P/S con-
taining fluorescently labeled zymosan particles (0.5 mg/ml) 
for 4 h at 37 °C, 5 % CO2. Fluorescence was measured with 
Victor X3™ microplate reader (Perkin-Elmer, Waltham, 
USA).
Statistical analysis
Statistical analyses were carried out using GraphPad Prism 
version 6.02 for Windows, GraphPad Software, San Diego, 
CA, USA, “www.graphpad.com”. All values in the figures 
are presented as mean ± SEM unless stated otherwise. 
Outliers were identified by ROUT analysis with Q = 1 %. 
Gaussian distribution was tested with D’Agostino and 
Pearson omnibus normality test, Shapiro–Wilk normal-
ity test and KS normality test. Variances were compared 
with F test. Unpaired t test with (unequal SD) or without 
(equal SD) Welch’s correction was used for unpaired data 
and paired t test for paired data from Gaussian distribution. 
Mann–Whitney test (unpaired data) or Wilcoxon matched-
pairs signed-rank test (paired data) was used for data from 
non-Gaussian distribution. All tests for significance were 
two tailed.
Results
Enrichment of classical CD14+CD16− monocytes 
in peripheral blood of PD patients
To investigate whether the composition of peripheral 
myeloid cells is altered in PD, we used a FACS-based 
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analysis to characterize different monocyte subpopula-
tions from PD patients and age-matched healthy controls. 
To avoid confounding factors affecting the immune sys-
tem all PD patients with acute inflammatory co-morbid-
ities were excluded from all following experiments. A 
detailed description of the PD patient cohort for each of 
the following experiments can be found as Supplemen-
tary Tables 1–5. We applied a FACS analysis strategy that 
was published recently [13], in which blood monocytes 
can be discriminated from the rest of the leukocytes based 
on high expression of HLA-DR and absence of B-cell 
(CD19−), T-cell (CD2−), NK-cell (CD335−), or granu-
locyte markers (CD15−). Within this cell population, clas-
sical (CD14+CD16−) and non-classical (CD14−CD16+) 
monocytes can be distinguished (Fig. 1a). We included the 
intermediate population (CD14+CD16+) to the non-clas-
sical population and refer to this combinatory population 
as CD16+ population according to Ziegler and Heitbrock 
[44]. Comparing total numbers of monocytes from PD 
patients and healthy controls revealed no significant differ-
ence (Fig. 1b). Interestingly, we found that in the periph-
eral blood of PD patients, classical monocytes (CD16−) 
are enriched, and concurrently, CD16+ monocytes are 
reduced compared to the monocyte composition from 
healthy donors (Fig. 1c). It has been suggested that a non-
coding variant of HLA-DR A influences the expression of 
HLA-DR [1, 42]. To control that HLA-DR expression did 
not influence our FACS results, we quantified HLA-DR-
positive monocytes in PD patients and healthy controls. As 
demonstrated in Supplementary Fig. 1, no significant dif-
ference in HLA-DR expression between the PD and control 
group was detected.
PD monocytes exhibit a dysregulation of inflammatory 
pathways
To investigate the transcriptome profile of peripheral mono-
cytes in PD and to identify molecular pathways which 
are differentially regulated compared to healthy controls, 
we purified peripheral blood monocytes from PD patients 
(n = 8) and healthy controls (n = 9) by positive magnetic 
selection, isolated total RNA and subjected it to next-gen-
eration sequencing. Detected transcripts were mapped to 
a whole-genome library and a total of 8,862 genes were 
expressed over the lower threshold (average FPKM >5, 
Fig. 2a). Strikingly, unsupervised hierarchical clustering 
(complete linkage by cosine correlation) revealed similar 
expression patterns among PD patients and largely sepa-
rated disease cases from healthy controls with only two 
exceptions (Fig. 2b).
A detailed analysis based on filtering genes by expres-
sion and significant difference between the disease and 
control groups revealed that genes which are differentially 
expressed in PD monocytes include transcription factors, 
secreted proteins and micro-RNAs (Fig. 2c, d).
Pathway (Table 1) and upstream (Table 2) analysis 
(IPA) demonstrated that the most significantly affected 
pathways are related to inflammation: granulocyte and 
agranulocyte adhesion, diapedesis, regulation of cytokine 
production, response to chemical stimulus and organic 
substances, response to stress and to LPS (Supplementary 
Table 6). Bacterial LPS, TGFβ, TNFα, PDGF and FAS 
Fig. 1  Classical (CD14+CD16−) monocytes are enriched in PD 
patients. a Representative FACS analysis of monocyte subpopulations 
from peripheral blood. Monocytes are gated out of other immune 
cells (FITC—CD2/CD15/CD19/CD335) by HLA-DR staining (PE-
Cy7) and monocyte subpopulations characterized based on CD14 
(PerCP-Cy5.5) and CD16 (PE) staining. b Total number of mono-
cytes in peripheral blood as a percentage of total leukocytes. No sig-
nificant difference between PD patients’ and healthy controls’ blood 
was found (Healthy controls n = 21, PD n = 14). c CD14+CD16− 
(classical) monocytes are enriched and CD14−/+CD16+ monocytes 
are decreased in the blood of PD patients. (Healthy controls n = 21, 
PD patients n = 14). Bars mean ± SEM, ****p < 0.0001
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were identified as most probably involved signal media-
tors (Table 2). In addition, we found that chemokine bind-
ing and activity, MAP-kinase signaling and cytokine sign-
aling are dysregulated in PD monocytes (Supplementary 
Table 7).
In accordance with the next-generation sequencing 
results from the PD discovery cohort, we could confirm by 
qRT-PCR in a separate validation cohort of 14 PD patients 
and 13 controls the highly significant downregulation of six 
mRNAs: JUN, EGR1, DUSP1, RHOB, FOS, NFKBIZ and 
a tendency for downregulation for FOSB (Fig. 2e).
PD monocytes are pathologically hyperactive in response 
to LPS stimulation and their hyperactivity is correlated 
to PD severity
To explore the physiological relevance of our findings 
and to test the hypothesis that the function of myeloid 
cells is altered in PD patients, we established a human 
primary monocyte culture system using positive mag-
netic selection based on CD14 expression and subsequent 
culture. The purity of the monocytic fraction was higher 
than 95 % (Supplementary Fig. 2a–c) and all monocytic 
Fig. 2  Transcriptome-wide analysis of gene expression in PD and 
healthy control monocytes by next-generation sequencing reveals a 
distinct expression signature in PD monocytes. a Heatmap of 8,862 
genes expressed over the threshold (FPKM >5). b Unsupervised hier-
archical clustering based on the expression of 8,862 genes in blood 
monocytes successfully identified most PD cases and clustered them 
away from healthy controls. Clustering by complete linkage and 
cosine correlation. c Differential expression of selected top genes in 
PD monocytes. d Fold change of expression in PD monocytes vs. 
healthy controls’ monocytes. e Validation of selected genes’ expres-
sion in an independent cohort (healthy controls n = 13, PD patients 
n = 14) by qRT-PCR. Bars represent mean ± SEM, *p < 0.05, 
**p < 0.01, ****p < 0.0001
Table 1  Top 5 differentially regulated canonical pathways in PD 
monocytes (ingenuity pathway analysis)
Ingenuity canonical pathways p value of overlap
Granulocyte adhesion and diapedesis 5.89E−09
Agranulocyte adhesion and diapedesis 1.05E−08
Differential regulation of cytokine production in 
macrophages and T helper cells by IL-17A and 
IL-17F
1.35E−08
Differential regulation of cytokine production in 
intestinal epithelial cells by IL-17A and IL-17F
5.25E−08
IL-17A signaling in fibroblasts 4.79E−07
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subpopulations were present in the monocytic fraction 
even when CD14 is expressed at low levels in non-classical 
monocytes (Supplementary Fig. 2d). To exclude the possi-
bility that anti-CD14 magnetic beads impair monocyte acti-
vation or pre-activate monocytes, IL-6 release was meas-
ured after LPS stimulation using both anti-CD14 positive 
and negative isolation methods. No difference in monocyte 
activation was detected, thereby ensuring the quality of our 
assay system (Supplementary Fig. 2e). Monocytes from PD 
patients and controls were then stimulated with LPS in cul-
ture. Strikingly, we found that monocytes from PD patients 
behave abnormally, displaying excessive pro-inflamma-
tory IL-1β, IL-6, IL-8 and IFNγ production compared to 
monocytes from age- and sex-matched healthy controls 
(Fig. 3a–d). Even though statistical significance was not 
reached (p = 0.06), a trend for increased TNFα and IL-10 
secretion was also observed for PD monocytes compared to 
control monocytes (Fig. 3e–f). The most striking increase 
of cytokine release upon LPS stimulation from PD mono-
cytes was found regarding IL-6 production (p < 0.0001) 
(Fig. 3g). Since most PD patients included in the study 
were on l-dopa treatment (see Supplementary Tables 1–5), 
we also tested the effect of l-dopa on IL-6 release in our 
monocyte cultures to rule out the possibility that l-dopa 
leads to an excess release of IL-6. As shown in Supplemen-
tary Fig. 3, l-dopa had no significant effect on IL-6 release 
of monocytes from healthy donors. Interestingly, we did 
not detect any excess production of cytokines by PD mono-
cytes compared to monocytes from healthy controls with-
out LPS stimulation.
We hypothesized that if monocyte hyperactivation 
upon LPS challenge is pathophysiologically relevant, the 
extent of monocyte hyperactivation should be reflected in 
clinical parameters. Indeed, we found that IL-6 secretion 
from LPS-stimulated monocytes derived from PD patients 
was strongly positively correlated with the Hoehn & Yahr 
(H&Y) stage of disease severity (Fig. 3h).
To further characterize the functional abnormalities of 
isolated PD monocytes, we assessed another main function 
of myeloid phagocytes—the phagocytosis of extracellular 
material. To this end, we applied a highly specific phago-
cytosis assay employing pH-sensitive-labeled yeast wall 
particles exhibiting a weak fluorescence at neutral pH and a 
dramatic increase in fluorescence at lower pH. This enables 
the quantification of cellular uptake and acidification of the 
phagocytic compartments. FACS analysis and microscopic 
pictures at the cellular level confirm the uptake of fluores-
cent particles (Supplementary Fig. 4). Using this phagocy-
tosis assay, we found a significant reduction in phagocytic 
activity in the monocytes of PD patients compared to those 
of healthy controls (Fig. 3i).
The CCR2–CCL2 axis is activated in PD
Classical monocytes are characterized by high expres-
sion of C–C chemokine receptor type 2 (CCR2) and are 
recruited from the bone marrow in a chemokine-dependent 
manner. C–C motif ligand 2 (CCL2, also known as mono-
cyte chemoattractant protein-1 MCP-1) is involved in 
monocyte recruitment from the bone marrow and spleen to 
the site of inflammation and is dependent on the presence 
of its receptor C–C chemokine receptor type 2 (CCR2) 
[43]. To further support the idea that PD patients exhibit 
altered monocyte function in the periphery and an ongo-
ing inflammatory reaction where monocytes could be 
potentially recruited from the bone marrow in a CCL2-
dependent manner, CCL2 measurements were performed 
from monocytes that were stimulated with LPS. Notably, 
Table 2  Top 5 predicted upstream regulators in PD monocytes (ingenuity upstream analysis)
Upstream regulator p value of overlap Target molecules in dataset
Lipopolysaccharide 3.57E−37 ATF3, CCL2, CCL3, CCL4, CD83, CD9, COL1A2, COL6A1, CTSK, CXCL1, CXCL2, DCN, DKK3, 
DUSP1, DUSP2, EGR1, EGR2, FOS, FOSB, G0S2, GPR183, HCAR3, HLA-DQA1, IGFBP4, 
IL1B, IL8, JUN, KLF4, KLF6, MME, MMP2, MMP9, NFKBIA, NFKBIZ, NR4A1, NR4A2, OLR1, 
PLIN2, PMAIP1, PPP1R15A, PTGS2, RGS1, RHOB, SERPINH1, SLAMF7, SPARC, TGM2, TNC, 
TPM2, TRIB1, ZFP36
PDGF BB 3.22E−36 ATF3, CCL2, CXCL2, DCN, DUSP1, EGR1, EGR2, FHL1, FOS, FOSB, GPR183, IER2, IGFBP4, 
IL1B, IL8, JUN, KLF6, MMP2, MMP9, NR4A1, NR4A2, OLR1, PPP1R15A, PTGS2, RGS1, 
RHOB, SCD, TGM2, TNC, TRIB1, ZFP36
TGFB1 6.24E−31 CCL2, CCL3, CCL4, CD83, CLU, COL1A2, COL6A1, COL6A2, CTSK, CXCL1, CXCL2, DCN, 
DKK3, DUSP1, ECM1, EGR1, EGR2, EMILIN1, FHL1, FOS, FOSB, HLA-DQA1, IER2, IGFBP4, 
IL1B, IL8, JUN, KLF4, LTBP2, MMP2, MMP9, NFKBIA, NR4A1, NR4A2, OLR1, PTGS2, 
RGCC, RHOB, SCD, SERPINH1, SERTAD1, SPARC, TGM2, TNC, TPM2, ZFP36
LDL 4.04E−30 ATF3, CCL2, CCL3, CCL4, CTSK, CXCL2, DUSP1, DUSP2, EGR1, FOS, FOSB, G0S2, GPR183, 
IGFBP4, IL1B, IL8, JUN, MMP2, MMP9, NR4A1, NR4A2, OLR1, PLIN2, PMAIP1, PTGS2
FAS 1.10E−29 CCL2, CCL3, CCL4, CD83, COL1A2, COL6A1, CXCL1, CXCL2, DUSP10, EGR1, EGR2, FOS, 
FOSB, GPNMB, HCAR3, IL1B, IL8, JUN, MME, MMP9, NFKBIA, NR4A1, NR4A2, PLIN2, 
PPP1R15A, TNC, TRIB1, ZFP36
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LPS stimulation of monocytes also led to an abnormal 
CCL2 release by PD monocytes compared to monocytes 
isolated from healthy donors (Fig. 4a). Most importantly, 
elevated levels of CCL2 were also detected in the serum 
of PD patients compared to age-matched healthy controls 
(Fig. 4b), thereby additionally supporting the relevance 
of our in vitro human primary monocyte culture system. 
Interestingly, the gene set enrichment analysis identified 
CCR chemokine receptor binding as one of the top affected 
molecular functions as well as CCL2 as top affected sig-
nal transduction pathway (Supplementary Table 7). Matrix 
metalloproteinase activity, which is important for the 
release, movement and migration of monocytes, was also 
amongst the top affected pathways.
To investigate whether the observed inflammatory dys-
regulation is specific for PD we also included patients 
with other parkinsonian symptoms like patients with 
multiple system atrophy (MSA) and progressive supra-
nuclear palsy (PSP) in our study. FACS-based analysis 
of monocytic subpopulations revealed an enrichment of 
classical monocytes also in PSP and MSA patients (Sup-
plementary Fig. 5b), whereas the number of total mono-
cytes was not significantly altered between the PD, PSP, 
MSA and control group (Supplementary Fig. 5a). LPS 
stimulation of cultured monocytes from PD patients 
and controls leads to an excess release of IL-6 from PD 
monocytes compared to controls as observed in our ini-
tial experiments. However, we also observed increased 
Fig. 3  PD monocytes are hyperactive upon LPS stimulation. Mono-
cytes from PD patients secrete significantly higher levels of IL-1β, 
IL-6, IL-8 and IFNγ when stimulated with 1 ng/ml LPS compared to 
monocytes from age-matched healthy controls (a–d). No significant 
difference in cytokine secretion was observed for TNFα (p = 0.05), 
and IL-10 (p = 0.52) (e, f). Bars represent mean ± SEM. PD 
patients (n = 10), healthy controls (n = 10), *p < 0.05, **p < 0.01, 
*** p < 0.001, ****p < 0.0001. g Fold increase in cytokine produc-
tion of monocytes from PD patients vs. healthy controls. h Correla-
tion between IL-6 release after 24 h stimulation with 1 ng/ml LPS 
and PD severity staged with the H&Y scale. Dotted lines indicate 
the 95 % CI of the linear regression. r Spearman’s correlation coef-
ficient. i Decreased phagocytic function of Parkinson’s disease mono-
cytes, healthy controls (n = 15), PD patients (n = 11). Bars represent 
mean ± SEM, *p < 0.05
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IL-6 release from PSP monocytes compared to controls. 
In contrast, MSA monocytes did not release excess IL-6 
upon LPS stimulation (Supplementary Fig. 5c). Regard-
ing phagocytic activity of cultured monocytes, we found 
only reduced phagocytic activity in PD monocytes. PSP 
and MSA monocytes had similar phagocytic activity than 
control monocytes (Supplementary Fig. 5d). We also 
measured CCL2 levels in the serum of PSP and MSA 
patients with no significant differences compared to con-
trol serum, whereas PD serum showed increased CCL2 
levels (Supplementary Fig. 5e).
FAS/FASLG system is involved in the dysregulation 
of monocyte subpopulations in PD patients
Another top upstream regulator identified by the gene 
set enrichment analysis is FAS, which has been previ-
ously linked to inflammatory processes in mouse models 
of inflammation [5]. In humans and in a mouse model for 
spinal cord lesion, upregulation of FAS ligand (FASLG) 
is required for the recruitment of peripheral myeloid cells 
to the injured tissue [31]. To determine whether the FAS/
FASLG system is involved in the peripheral dysregulation 
Fig. 4  The CCR2–CCL2 axis 
is activated in PD. a Mono-
cytes from PD patients release 
significantly higher levels of 
CCL2 upon LPS stimulation 
(LPS 1 ng/ml, healthy controls 
n = 10, Parkinson’s disease 
patients n = 10, *p < 0.05). b 
CCL2 is significantly increased 
(*p < 0.05) in the serum of 
PD patients (n = 53) when 
compared to healthy controls 
(n = 34). Bars represent 
mean ± SEM
Fig. 5  FAS/FASLG upregula-
tion in monocytes from PD 
patients. The expression of 
both FAS (a) and FASLG (b) is 
upregulated in unstimulated PD 
monocytes (Healthy controls 
n = 14, PD patients n = 14). 
c Monocytes are enriched in 
PD leukocyte cultures after 
48 h treatment with FASLG-
inhibitor APG101 (n = 15, 
APG 0.25 mg/ml). d Classical 
(CD14+CD16−) monocytes 
are decreased and non-classical 
(CD14−CD16+) monocytes 
are increased by treatment of 
PD leukocytes with APG101 in 
culture (n = 15). Bars represent 
mean ± SEM. *p < 0.05, 
**p < 0.01, ***p < 0.001, 
****p < 0.0001
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of monocytes in PD, FAS and FASLG expression levels 
in monocytes from PD patients were measured. Strik-
ingly, a strong upregulation of both FAS and FASLG in 
monocytes from PD patients was observed (Fig. 5a, b). 
Importantly, deletion of myeloid FASLG or neutraliza-
tion of FASLG on myeloid cells was reported to improve 
functional recovery after CNS trauma [31]. We, therefore, 
asked whether neutralization of FASLG would also have 
therapeutic effects on the regulation of monocyte subpop-
ulations in PD patients. To this end, leukocytes derived 
from erythrocyte-depleted whole blood of PD patients 
was treated with the FASLG antagonist APG101 [41] 
for 48 h in culture. Using an FACS-based approach, we 
found a therapeutic effect of APG101 by a 2.5-fold reduc-
tion of the ratio of classical to non-classical monocytes 
derived from PD patients compared to vehicle-treated 
cells (Fig. 5d). The same reduction of the ratio of classical 
to non-classical monocytes was observed for healthy con-
trols (Supplementary Fig. 6).
Discussion
Using a multimodal approach, we identified a dysregu-
lation of peripheral human monocytes in PD. We have 
shown that PD monocytes have a pro-inflammatory pre-
disposition based on their transcriptome profile and dis-
balance of monocytic subpopulations. The increased ratio 
in pro-inflammatory classical monocytes in PD patients 
was accompanied by an activation of the CCR2–CCL2 
axis in PD. Moreover, using a human primary mono-
cyte culture system we were able to demonstrate that PD 
monocytes respond to a “second hit” with hyperactivation, 
which correlated with clinical disease stages. Finally, we 
demonstrate that the FAS/FASLG system is essentially 
involved in deregulation of monocyte subpopulations, 
which can be pharmacologically reverted by neutraliza-
tion of FASLG.
In the transcriptome analysis, we found that the response 
to inflammatory triggers is dysregulated on a transcrip-
tional level in PD. This dysregulation could also be con-
firmed in an independent cohort on the basis of the single 
genes JUN, FOSB, EGR1, DUSP1, RHOB, FOS and NFK-
BIZ. Thus, PD monocytes were preconditioned to behave 
abnormally upon inflammatory stimulation. However, our 
work was not designed as a classical biomarker study. We 
did not investigate the correlation of mRNA levels of spe-
cific genes in monocytes and disease severity. This would 
possibly require larger and or more homogenous PD 
patient cohorts including, for example, the exclusion of 
specific mutations in PARK genes. Nevertheless, the find-
ings of this study could be the basis for the development of 
easily accessible PD biomarkers in the blood of PD patients 
and might turn out to be valuable readouts to judge future 
clinical studies on disease-modifying therapies. In a com-
plementary approach using a FACS-based technology, we 
were able to confirm a pro-inflammatory dysregulation of 
monocytic subpopulations.
These primary abnormalities of PD monocytes suggest 
that monocytes from PD patients also behave functionally 
different, supported by an impaired phagocytic function 
of PD monocytes (this study and [23]). Since monocyte-
derived CNS macrophages can contribute to the resolu-
tion of neuroinflammation by clearing of cell debris and 
extracellular material [19], a decrease of phagocytic activ-
ity could be detrimental. Additional proof for functional 
abnormalities of monocytes in PD patients comes from 
our primary human monocyte culture system. Unlike the 
study of Hasegawa et al. [27], we found functional over-
activity upon LPS stimulation of cultured monocytes from 
PD patients compared to healthy controls. The discrepancy 
to the study of Hasegawa et al. who found lower levels of 
certain cytokines (IL-1β, TNFα, IL-6 and IFNγ) released 
by PBMCs might be explained by the monocyte isolation 
method. While Hasegawa et al. used gradient density sedi-
mentation leading ultimately to the isolation of monocytes 
and lymphocytes (contained in the PBMC fraction), we 
used positive magnetic selection based on CD14 expres-
sion leading to the isolation of solely monocytes. Addition-
ally, when Hasegawa et al. enriched monocytes in culture 
by changing the media they could not confirm decreased 
cytokine release in their cultures suggesting that the lym-
phocytes contained in the culture of Hasegawa et al. and 
the isolation method account for the discrepancy of the 
two studies. Strikingly, increased cytokine secretion from 
PD monocytes upon LPS stimulation correlated in our 
study with PD disease state, thereby suggesting that mono-
cyte hyperactivation is linked to disease severity. Collec-
tively, our findings indicate that myeloid cells of the innate 
immune system are functionally altered and point to a pro-
inflammatory predisposition of the innate immune system 
of PD patients.
Most importantly, PD monocytes were not functionally 
overactive a priori but required a “second hit” to exert their 
abnormal activity. Such “second hits” could be environmen-
tal cues or CNS factors triggering the peripheral immune 
system. Strong support for this theory comes from the study 
of Gao et al. [22], who showed that LPS-induced inflamma-
tion and alpha-synuclein pathology act synergistically and 
potentiate neurodegeneration in a genetic mouse model of 
PD. Similarly, recent studies demonstrated that repeated 
LPS injections exacerbated the pathogenesis of ALS in a 
mouse model system [33] and impaired the behavioral phe-
notype in prion-diseased animals [14]. Our results suggest 
that the progression or development of neurological diseases 
might be affected by the number and type of environmental 
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second hits in conjunction with an existing predisposition. 
Our data from PD monocytes and previous experimental 
evidence are complemented by the association of influenza 
infections, asthma and allergic rhinitis to the development of 
PD [7, 26]. Our data might also provide an explanation for 
the clinical observation that PD patients often do not fully 
recover from worsened PD symptoms after severe systemic 
infections. However, further studies are needed to translate 
our findings to clinical therapies.
The increase of classical CD14+CD16− monocytes 
and decrease in the non-classical CD14−CD16+ mono-
cytes in the blood of PD patients observed in this study 
could result from both differentiation of monocytes and 
monocyte precursors to the classical pro-inflammatory 
phenotype or from increased migration from the bone mar-
row. Support for the latter comes from our observation 
of elevated levels of CCL2 in the serum of PD patients, 
a classical signal for recruitment of monocytes from the 
bone marrow [37]. In agreement with this idea, Funk et 
al. demonstrated an upregulation of surface CCL2 recep-
tor (CCR2) on classical monocytes of PD patients [21]. 
The elevated serum levels of CCL2 in PD could possibly 
be attributed to the increased production of the chemokine 
by monocytes themselves. In line with this, we found that 
upon LPS stimulation, PD monocytes secrete significantly 
higher levels of CCL2 compared to control monocytes. 
Together, these results suggest that the CCR2–CCL2 axis 
ranging from CCL2 release to altered composition of 
monocytes is activated in PD. These results are also in 
agreement with previous studies [6, 35] demonstrating ele-
vated LPS-induced CCL2 production from PD monocytes. 
CCL2 release by monocytes could be a part of a feedback 
loop serving to enhance the further recruitment of mono-
cytes to the inflammatory site. Interestingly, activated 
microglia can also secrete CCL2 [16], which can cross 
the blood–brain barrier and recruit monocytes into the 
inflamed CNS. Reactive microgliosis has been observed 
in the affected PD brain regions and is hypothesized to be 
triggered by extracellular alpha-synuclein and apoptotic 
neurons [25]. Thus, the increased CCL2 serum levels and 
increase of classical monocytes in our PD cohort could 
possibly also be a result of the secretion of inflammatory 
mediators by microglia.
To gain more insight in the specificity of the observed 
dysregulation of peripheral human monocytes in PD, we 
also included PSP and MSA patients as another disease 
cohort with parkinsonian symptoms. Overall, we found 
evidence for inflammatory dysregulation also in PSP and 
MSA with regard to some aspects (enrichment of classi-
cal monocytes, increased IL-6 release upon LPS stimula-
tion for the PSP cohort), while other changes are clearly 
specific for PD (decreased phagocytic activity, increased 
CCL2 serum levels for MSA). However, it has to be taken 
into account that due to the limited number of MSA and 
PSP patients a definitive statement regarding inflammatory 
dysregulation in PSP and MSA remains difficult. Further 
studies including larger patient numbers for MSA and PSP 
are needed to fully understand the biology of peripheral 
monocytes in MSA and PSP.
Three pieces of evidence in our study suggest an essen-
tial involvement of the FAS/FASLG system in the dys-
regulation of PD monocytes. First, we found a strong 
upregulation of both FAS and FASLG in monocytes from 
PD patients. Second, the transcriptome gene set enrich-
ment analysis identified FAS as a top upstream regulator 
of dysregulated genes in PD monocytes. Finally, phar-
macological neutralization of FASLG could reverse the 
increased ratio of classical to non-classical monocytes in 
PD patients and controls in vitro suggesting that the FAS/
FASLG system plays a crucial role in the regulation of 
human monocyte subpopulations. Our results are also in 
line with the findings of Brochard et al. [8] describing an 
FASLG-dependent dopaminergic toxicity in MPTP-treated 
mice. Neutralization of FASLG could hold a therapeutic 
promise, and clinical studies based on the FASLG neu-
tralizing fusion protein used in our study (APG101) are 
clearly warranted. Importantly, APG101 has already been 
successfully applied to patients and turned out to be safe in 
a neuro-oncological context [41]. However, further stud-
ies are needed to fully translate our findings into clinical 
therapies.
In summary, our findings provide the first direct evidence 
that circulating myeloid cells are altered in terms of their 
transcriptome profile, subset composition, and function in 
PD patients. Furthermore, we present the FAS/FASLG sys-
tem as a regulator of monocyte subpopulations which could 
be targeted in pharmacological approaches to treat PD. A 
better understanding of monocyte function and the role of 
the FAS/FASLG system as well as first safety and proof-of-
principle studies in PD patients using APG101 may pave the 
way to novel therapies aimed at halting disease progression 
in PD patients.
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